MX352823B - Formulaciones de proteinas que contienen aminoacidos. - Google Patents
Formulaciones de proteinas que contienen aminoacidos.Info
- Publication number
- MX352823B MX352823B MX2014005106A MX2014005106A MX352823B MX 352823 B MX352823 B MX 352823B MX 2014005106 A MX2014005106 A MX 2014005106A MX 2014005106 A MX2014005106 A MX 2014005106A MX 352823 B MX352823 B MX 352823B
- Authority
- MX
- Mexico
- Prior art keywords
- amino acids
- formulations containing
- containing amino
- protein
- protein formulations
- Prior art date
Links
- 150000001413 amino acids Chemical class 0.000 title abstract 6
- 238000009472 formulation Methods 0.000 title abstract 5
- 239000000203 mixture Substances 0.000 title abstract 5
- 102000004169 proteins and genes Human genes 0.000 title abstract 4
- 108090000623 proteins and genes Proteins 0.000 title abstract 4
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/47—Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
- A61K38/482—Serine endopeptidases (3.4.21)
- A61K38/4846—Factor VII (3.4.21.21); Factor IX (3.4.21.22); Factor Xa (3.4.21.6); Factor XI (3.4.21.27); Factor XII (3.4.21.38)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/55—Protease inhibitors
- A61K38/57—Protease inhibitors from animals; from humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39591—Stabilisation, fragmentation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
- C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
- C07K16/1027—Paramyxoviridae, e.g. respiratory syncytial virus
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/241—Tumor Necrosis Factors
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2887—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
- C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
- C12Y302/01045—Glucosylceramidase (3.2.1.45), i.e. beta-glucocerebrosidase
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
- C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
- C12Y302/01022—Alpha-galactosidase (3.2.1.22)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
- C12Y304/21—Serine endopeptidases (3.4.21)
- C12Y304/21022—Coagulation factor IXa (3.4.21.22)
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Gastroenterology & Hepatology (AREA)
- Virology (AREA)
- Zoology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Pulmonology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Oncology (AREA)
- General Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
Abstract
La presente invención se refiere a formulaciones estables de proteínas que contienen al menos un aminoácido. En ciertas modalidades, se incluyen combinaciones de aminoácidos, ya sea por lo menos dos, o tres, o cuatro o más aminoácidos. En virtud de la inclusión de los aminoácidos, la formulación tiene baja viscosidad y una proteína en las formulaciones es física, química y biológicamente estable incluso en altas concentraciones. En otras modalidades, en virtud de la inclusión de los aminoácidos, una proteína en las formulaciones es física, química y biológicamente estable incluso en altas concentraciones.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201161552688P | 2011-10-28 | 2011-10-28 | |
PCT/US2012/062282 WO2013063510A1 (en) | 2011-10-28 | 2012-10-26 | Protein formulations containing amino acids |
Publications (2)
Publication Number | Publication Date |
---|---|
MX2014005106A MX2014005106A (es) | 2014-09-22 |
MX352823B true MX352823B (es) | 2017-12-04 |
Family
ID=48168607
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2014005106A MX352823B (es) | 2011-10-28 | 2012-10-26 | Formulaciones de proteinas que contienen aminoacidos. |
Country Status (9)
Country | Link |
---|---|
US (3) | US9364542B2 (es) |
EP (2) | EP3578203A1 (es) |
KR (2) | KR101759694B1 (es) |
CN (2) | CN108771655A (es) |
AU (2) | AU2012328524B2 (es) |
BR (1) | BR112014010186A2 (es) |
CA (2) | CA2951856A1 (es) |
MX (1) | MX352823B (es) |
WO (1) | WO2013063510A1 (es) |
Families Citing this family (94)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP3578205A1 (en) | 2010-08-06 | 2019-12-11 | ModernaTX, Inc. | A pharmaceutical formulation comprising engineered nucleic acids and medical use thereof |
WO2012045082A2 (en) | 2010-10-01 | 2012-04-05 | Jason Schrum | Engineered nucleic acids and methods of use thereof |
AU2012236099A1 (en) | 2011-03-31 | 2013-10-03 | Moderna Therapeutics, Inc. | Delivery and formulation of engineered nucleic acids |
US9464124B2 (en) | 2011-09-12 | 2016-10-11 | Moderna Therapeutics, Inc. | Engineered nucleic acids and methods of use thereof |
EP3682905B1 (en) | 2011-10-03 | 2021-12-01 | ModernaTX, Inc. | Modified nucleosides, nucleotides, and nucleic acids, and uses thereof |
EP3578203A1 (en) | 2011-10-28 | 2019-12-11 | Integritybio Inc. | Protein formulations containing amino acids |
DK2791160T3 (da) | 2011-12-16 | 2022-05-30 | Modernatx Inc | Modificerede mrna-sammensætninger |
US9283287B2 (en) | 2012-04-02 | 2016-03-15 | Moderna Therapeutics, Inc. | Modified polynucleotides for the production of nuclear proteins |
US9572897B2 (en) | 2012-04-02 | 2017-02-21 | Modernatx, Inc. | Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins |
US9878056B2 (en) | 2012-04-02 | 2018-01-30 | Modernatx, Inc. | Modified polynucleotides for the production of cosmetic proteins and peptides |
DE18200782T1 (de) | 2012-04-02 | 2021-10-21 | Modernatx, Inc. | Modifizierte polynukleotide zur herstellung von proteinen im zusammenhang mit erkrankungen beim menschen |
FR2994390B1 (fr) | 2012-08-10 | 2014-08-15 | Adocia | Procede d'abaissement de la viscosite de solutions de proteines a concentration elevee |
HUE049282T2 (hu) | 2012-09-07 | 2020-09-28 | Coherus Biosciences Inc | Adalimumab stabil vizes formulációi |
HRP20220607T1 (hr) | 2012-11-26 | 2022-06-24 | Modernatx, Inc. | Terminalno modificirana rna |
US9669010B2 (en) * | 2012-12-06 | 2017-06-06 | Bio Health Solutions, Llc | Treatment for chronic kidney disease |
SG10201913932VA (en) | 2013-03-13 | 2020-03-30 | Genentech Inc | Antibody formulations |
US8980864B2 (en) | 2013-03-15 | 2015-03-17 | Moderna Therapeutics, Inc. | Compositions and methods of altering cholesterol levels |
EP3808338A1 (en) | 2013-09-11 | 2021-04-21 | Eagle Biologics, Inc. | Liquid protein formulations containing ionic liquids |
EP3052521A1 (en) | 2013-10-03 | 2016-08-10 | Moderna Therapeutics, Inc. | Polynucleotides encoding low density lipoprotein receptor |
CN113350278B (zh) * | 2013-10-24 | 2023-03-24 | 阿斯利康(瑞典)有限公司 | 稳定的水性抗体配制品 |
CA2924448C (en) * | 2013-11-29 | 2021-12-14 | Genentech, Inc. | Antibody selection apparatus and methods |
KR20230097209A (ko) | 2014-03-12 | 2023-06-30 | 예다 리서치 앤드 디벨럽먼트 캄파니 리미티드 | Cns의 질환 및 손상을 치료하기 위한 전신적 조절 t 세포 수준 또는 활성의 감소 |
US10519237B2 (en) | 2014-03-12 | 2019-12-31 | Yeda Research And Development Co. Ltd | Reducing systemic regulatory T cell levels or activity for treatment of disease and injury of the CNS |
US9394365B1 (en) | 2014-03-12 | 2016-07-19 | Yeda Research And Development Co., Ltd | Reducing systemic regulatory T cell levels or activity for treatment of alzheimer's disease |
US10618963B2 (en) | 2014-03-12 | 2020-04-14 | Yeda Research And Development Co. Ltd | Reducing systemic regulatory T cell levels or activity for treatment of disease and injury of the CNS |
CA2944330A1 (en) * | 2014-04-02 | 2015-10-08 | Intas Pharmaceuticals Limited | Liquid pharmaceutical composition of adalimumab |
US10689460B2 (en) | 2014-05-15 | 2020-06-23 | Incube Labs, Llc | PCSK9 antibody preparations for delivery into a lumen of the intestinal tract using a swallowable drug delivery device |
US10098931B2 (en) * | 2014-05-15 | 2018-10-16 | Incube Labs, Llc | Pharmaceutical compositions and methods for fabrication of solid masses comprising immunoglobulins |
US11357857B2 (en) | 2014-06-20 | 2022-06-14 | Comera Life Sciences, Inc. | Excipient compounds for protein processing |
US10478498B2 (en) | 2014-06-20 | 2019-11-19 | Reform Biologics, Llc | Excipient compounds for biopolymer formulations |
US20160074515A1 (en) | 2014-06-20 | 2016-03-17 | Reform Biologics, Llc | Viscosity-reducing excipient compounds for protein formulations |
US20160137727A1 (en) | 2014-09-15 | 2016-05-19 | Genentech, Inc. | Antibody formulations |
AU2015325055B2 (en) | 2014-10-01 | 2021-02-25 | Eagle Biologics, Inc. | Polysaccharide and nucleic acid formulations containing viscosity-lowering agents |
BR112017008125B1 (pt) * | 2014-10-23 | 2023-11-21 | Amgen Inc. | Método para a redução da viscosidade de formulações farmacêuticas, formulações farmacêuticas, método de preparação de um pó liofilizado, pó liofilizado e método para reconstituição de um pó liofilizado |
CN107708723B (zh) * | 2015-04-21 | 2021-04-13 | 舒泰神(北京)生物制药股份有限公司 | 神经生长因子组合物和注射粉剂 |
TW202340452A (zh) | 2015-08-04 | 2023-10-16 | 美商再生元醫藥公司 | 補充牛磺酸之細胞培養基及用法 |
RS64263B1 (sr) * | 2015-08-19 | 2023-07-31 | Astrazeneca Ab | Stabilna anti-ifnar1 formulacija |
US11229702B1 (en) | 2015-10-28 | 2022-01-25 | Coherus Biosciences, Inc. | High concentration formulations of adalimumab |
EP3443346B1 (en) * | 2016-04-13 | 2023-08-30 | Medimmune, LLC | Use of amino acids as stabilizing compounds in pharmaceutical compositions containing high concentrations of protein-based therapeutic agents |
US11071782B2 (en) | 2016-04-20 | 2021-07-27 | Coherus Biosciences, Inc. | Method of filling a container with no headspace |
WO2017192993A1 (en) | 2016-05-05 | 2017-11-09 | Liquidia Technologies, Inc. | Dry powder treprostinil for the treatment of pulmonary hypertension |
US10858422B2 (en) | 2016-05-31 | 2020-12-08 | Abcentra, Llc | Methods for treating systemic lupus erythematosus with an anti-apolipoprotein B antibody |
WO2017210360A1 (en) | 2016-05-31 | 2017-12-07 | Cardiovax, Llc | Methods for diagnosing and treating systemic lupus erythematosus |
ES2770674T3 (es) * | 2016-06-10 | 2020-07-02 | Octapharma Ag | Composición de inmunoglobulinas de alta concentración para aplicaciones farmacéuticas |
WO2018050874A1 (en) | 2016-09-16 | 2018-03-22 | Leukocare Ag | A novel method of producing a liquid biopharmaceutical drug product |
EP3512939A1 (en) | 2016-09-16 | 2019-07-24 | Leukocare AG | A novel method for obtaining efficient viral vector-based compositions for vaccination or gene therapy |
US11510871B2 (en) | 2016-09-16 | 2022-11-29 | Leukocare Ag | Method for producing low viscous and highly concentrated biopharmaceutical drug products in liquid formulation |
RU2744630C2 (ru) * | 2016-09-16 | 2021-03-12 | Льюкокэар Аг | Новый способ стабилизации биофармацевтического лекарственного продукта при производстве |
MA46334A (fr) | 2016-09-27 | 2019-08-07 | Fresenius Kabi Deutschland Gmbh | Composition pharmaceutique liquide |
HUE054858T2 (hu) | 2016-10-31 | 2021-10-28 | Fresenius Kabi Deutschland Gmbh | Folyékony gyógyszerészeti készítmény |
JP7116059B2 (ja) | 2016-11-21 | 2022-08-09 | ジャスト-エヴォテック バイオロジックス、インコーポレイテッド | アフリベルセプト製剤及びその使用 |
RU2761249C2 (ru) * | 2016-12-14 | 2021-12-06 | Мерк Шарп энд Доум Корп. | Человеческие генетические маркеры, ассоциированные с ответом на средства для лечения, которые целенаправленно воздействуют на токсин b clostridium difficile |
WO2018107388A1 (en) * | 2016-12-14 | 2018-06-21 | Merck Sharp & Dohme Corp. | Human genetic markers associated with response to treatments that target clostridium difficile toxin b |
CN108261391B (zh) | 2016-12-30 | 2022-03-01 | 江苏太平洋美诺克生物药业有限公司 | 稳定的包含cd147单克隆抗体的药物制剂 |
BR112019010949A2 (pt) | 2017-01-11 | 2019-10-01 | Ferring Bv | composição farmacêutica de desintegração rápida |
KR102572453B1 (ko) * | 2017-02-16 | 2023-08-29 | 코메라 라이프 사이언시스, 인코포레이티드 | 단백질 가공 처리를 위한 부형제 화합물 |
CA3056919A1 (en) * | 2017-03-26 | 2018-10-04 | Vivi Robyn Stafford | Method of treatment of skin conditions of eye lids |
US11603407B2 (en) | 2017-04-06 | 2023-03-14 | Regeneron Pharmaceuticals, Inc. | Stable antibody formulation |
JOP20190255A1 (ar) | 2017-04-28 | 2019-10-27 | Amgen Inc | صيغ أجسام مضادة لـ rankl بشري، وطرق لاستخدامها |
US20200352857A1 (en) | 2017-04-28 | 2020-11-12 | Amgen Inc. | Excipients to reduce the viscosity of antibody formulations and formulation compositions |
EP3624846B1 (en) | 2017-05-16 | 2024-08-07 | Bhami's Research Laboratory, Pvt. Ltd. | High concentration protein formulations with reduced viscosity including a combination of nicotinic acid and tryoptophan |
CN111356471A (zh) * | 2017-11-20 | 2020-06-30 | 济世发展生物药业有限公司 | 包含赖氨酸盐作为张力调节剂的阿柏西普制剂及其用途 |
CN108014338A (zh) * | 2018-01-22 | 2018-05-11 | 安徽未名生物医药有限公司 | 一种注射用巴利昔单抗冻干粉针及其制备方法 |
WO2019147824A1 (en) | 2018-01-26 | 2019-08-01 | Progenity, Inc. | Treatment of a disease of the gastrointestinal tract with a pde4 inhibitor |
CN108079285B (zh) * | 2018-02-06 | 2021-01-01 | 昆明龙津药业股份有限公司 | 用于蛇毒酶制剂的门冬氨酸稳定剂及制备方法 |
EP3790532A1 (en) | 2018-05-10 | 2021-03-17 | Regeneron Pharmaceuticals, Inc. | High concentration vegf receptor fusion protein containing formulations |
WO2019246312A1 (en) | 2018-06-20 | 2019-12-26 | Progenity, Inc. | Treatment of a disease of the gastrointestinal tract with an immunomodulator |
US20230009902A1 (en) | 2018-06-20 | 2023-01-12 | Progenity, Inc. | Treatment of a disease or condition in a tissue orginating from the endoderm |
US20230312700A1 (en) | 2018-06-20 | 2023-10-05 | Progenity, Inc. | Treatment of a disease of the gastrointestinal tract with a tnf inhibitor |
WO2019246455A1 (en) | 2018-06-20 | 2019-12-26 | Progenity, Inc. | Treatment of a disease of the gastrointestinal tract with an integrin inhibitor |
WO2019246273A1 (en) | 2018-06-20 | 2019-12-26 | Progenity, Inc. | Treatment of a disease of the gastrointestinal tract with a jak or other kinase inhibitor |
US20210363233A1 (en) | 2018-06-20 | 2021-11-25 | Progenity, Inc. | Treatment of a disease of the gastrointestinal tract with an il-12/il-23 inhibitor |
WO2020055679A2 (en) * | 2018-09-10 | 2020-03-19 | Dow Global Technologies Llc | A composition comprising a protein and a polyalkoxy fatty acyl surfactant |
WO2020060179A1 (ko) * | 2018-09-18 | 2020-03-26 | 삼성바이오에피스 주식회사 | 완충화제를 포함하지 않는 트라스투주맙 항체 안정화 제제 |
WO2020071876A1 (ko) * | 2018-10-04 | 2020-04-09 | 삼성바이오에피스 주식회사 | 점도가 감소된 고농도 트라스투주맙 또는 이의 항원 결합 단편 안정화 제제 |
CN111195234B (zh) * | 2018-11-16 | 2022-08-26 | 鲁南制药集团股份有限公司 | 一种重组FGF21-Fc融合蛋白冻干粉制剂 |
CN111228225B (zh) * | 2018-11-28 | 2022-08-26 | 鲁南制药集团股份有限公司 | 一种重组人肿瘤坏死因子受体-Fc融合蛋白冻干制剂 |
US11767526B2 (en) | 2019-01-23 | 2023-09-26 | Regeneron Pharmaceuticals, Inc. | Treatment of ophthalmic conditions with angiopoietin-like 7 (ANGPTL7) inhibitors |
US11845989B2 (en) | 2019-01-23 | 2023-12-19 | Regeneron Pharmaceuticals, Inc. | Treatment of ophthalmic conditions with angiopoietin-like 7 (ANGPTL7) inhibitors |
US20220213223A1 (en) | 2019-02-12 | 2022-07-07 | Prothena Biosciences Limited | Treatment of Al Amyloidosis with the Combination of Monoclonal Antibodies Agains Immunoglobulin Light Chains and the CD38 Cell Membrane Molecule on Antibody-Producing And Other Immune Cells |
CA3132780A1 (en) | 2019-03-05 | 2020-09-10 | Prothena Biosciences Limited | Methods of treating al amyloidosis |
EP3725370A1 (en) | 2019-04-19 | 2020-10-21 | ImmunoBrain Checkpoint, Inc. | Modified anti-pd-l1 antibodies and methods and uses for treating a neurodegenerative disease |
CN110124030A (zh) * | 2019-06-10 | 2019-08-16 | 通化东宝生物科技有限公司 | 一种苏金单抗注射液及其制备方法 |
BR102019016950A2 (pt) * | 2019-08-15 | 2021-02-23 | Inst De Pesquisa Ensino Ciencia E Tecnologia Aplicada Inst Galzu | forma de dosagem intrauretral de medicamento; e dispositivo |
MY193349A (en) * | 2019-12-06 | 2022-10-06 | Regeneron Pharma | Anti-vegf protein compositions and methods for producing the same |
KR20220001106A (ko) | 2020-06-29 | 2022-01-05 | (주)메디톡스 | 고농도 항-vegf 항체 제제 및 이에 사용하기 위한 항-vegf 항체 |
KR20220028972A (ko) * | 2020-08-31 | 2022-03-08 | (주)셀트리온 | 안정한 약제학적 제제 |
EP4298219A1 (en) | 2021-02-26 | 2024-01-03 | Regeneron Pharmaceuticals, Inc. | Treatment of inflammation with glucocorticoids and angiopoietin-like 7 (angptl7) inhibitors |
KR20230134822A (ko) * | 2022-03-15 | 2023-09-22 | 주식회사 녹십자 | α-갈락토시다제 A의 융합단백질을 포함하는 액상 제제 |
KR20230134823A (ko) * | 2022-03-15 | 2023-09-22 | 주식회사 녹십자 | α-갈락토시다제 A의 융합단백질을 포함하는 동결 건조 제제 |
KR20230167968A (ko) * | 2022-06-03 | 2023-12-12 | 주식회사 녹십자홀딩스 | 점도 감소 부형제 조성물 및 이를 포함하는 저점도 고농축 단백질 제형 |
TW202417038A (zh) | 2022-06-15 | 2024-05-01 | 法商賽諾菲公司 | 高度濃縮的抗體組成物 |
KR102544928B1 (ko) * | 2022-12-28 | 2023-06-20 | 주식회사 중앙백신연구소 | 아미노산을 유효성분으로 함유하는 동물용 백신 또는 진단용 항원의 안정성 증진용 조성물 및 이의 용도 |
CN118048353A (zh) * | 2024-03-07 | 2024-05-17 | 海南华研胶原科技股份有限公司 | 一种亚氨基酸特异性内切蛋白酶复配酶制剂及制备方法 |
Family Cites Families (23)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5358708A (en) | 1993-01-29 | 1994-10-25 | Schering Corporation | Stabilization of protein formulations |
US5874075A (en) | 1993-10-06 | 1999-02-23 | Amgen Inc. | Stable protein: phospholipid compositions and methods |
AU783306B2 (en) | 1999-10-04 | 2005-10-13 | Novartis Vaccines And Diagnostics, Inc. | Stabilized liquid polypeptide-containing pharmaceutical compositions |
JP5485489B2 (ja) | 2000-08-11 | 2014-05-07 | 中外製薬株式会社 | 抗体含有安定化製剤 |
SI1324776T2 (en) | 2000-10-12 | 2018-06-29 | Genentech, Inc. | Concentrated protein formulations with reduced viscosity |
US20030104996A1 (en) | 2001-08-30 | 2003-06-05 | Tiansheng Li | L-methionine as a stabilizer for NESP/EPO in HSA-free formulations |
US20040022792A1 (en) | 2002-06-17 | 2004-02-05 | Ralph Klinke | Method of stabilizing proteins at low pH |
ATE424215T1 (de) | 2003-01-08 | 2009-03-15 | Novartis Vaccines & Diagnostic | Stabilisierte wässrige zusammensetzungen mit gewebefaktorinhibitor (tfpi) oder gewebefaktorinhibitor-variante |
AU2004229335C1 (en) | 2003-04-04 | 2010-06-17 | Genentech, Inc. | High concentration antibody and protein formulations |
EP1532983A1 (en) | 2003-11-18 | 2005-05-25 | ZLB Bioplasma AG | Immunoglobulin preparations having increased stability |
DE102004011663B4 (de) | 2004-03-10 | 2006-04-27 | Bioceuticals Arzneimittel Ag | Erythropoietin-Flüssigformulierung |
JP5627181B2 (ja) * | 2005-09-07 | 2014-11-19 | アルケミア オンコロジー ピーティーワイ リミテッド | ヒアルロナンおよび治療用抗体を含む治療用組成物ならびに治療方法 |
WO2007074880A1 (ja) * | 2005-12-28 | 2007-07-05 | Chugai Seiyaku Kabushiki Kaisha | 抗体含有安定化製剤 |
KR20080098504A (ko) * | 2006-02-03 | 2008-11-10 | 메디뮨 엘엘씨 | 단백질 제제 |
TW200806317A (en) | 2006-03-20 | 2008-02-01 | Wyeth Corp | Methods for reducing protein aggregation |
EP2129401B8 (en) | 2006-12-21 | 2020-01-15 | Amgen Inc. | Stable buffered formulations containing polypeptides |
PE20091174A1 (es) | 2007-12-27 | 2009-08-03 | Chugai Pharmaceutical Co Ltd | Formulacion liquida con contenido de alta concentracion de anticuerpo |
WO2010056657A2 (en) | 2008-11-16 | 2010-05-20 | Board Of Regents, The Univesity Of Texas System | Low viscosity highly concentrated suspensions |
CA2788863C (en) | 2010-02-04 | 2020-07-07 | Reinhard Franz Bolli | Immunoglobulin preparation |
MX2012009755A (es) * | 2010-02-26 | 2012-09-12 | Novo Nordisk As | Composiciones que contienen anticuerpo estable. |
NZ602685A (en) * | 2010-03-01 | 2014-10-31 | Cytodyn Inc | Concentrated protein formulations and uses thereof |
CA2832556A1 (en) * | 2011-04-07 | 2012-10-11 | Glaxosmithkline Llc | Formulations with reduced viscosity |
EP3578203A1 (en) | 2011-10-28 | 2019-12-11 | Integritybio Inc. | Protein formulations containing amino acids |
-
2012
- 2012-10-26 EP EP19166363.2A patent/EP3578203A1/en not_active Withdrawn
- 2012-10-26 EP EP12843696.1A patent/EP2771033A4/en not_active Withdrawn
- 2012-10-26 AU AU2012328524A patent/AU2012328524B2/en active Active
- 2012-10-26 CN CN201810084169.8A patent/CN108771655A/zh active Pending
- 2012-10-26 MX MX2014005106A patent/MX352823B/es active IP Right Grant
- 2012-10-26 KR KR1020147014382A patent/KR101759694B1/ko active IP Right Grant
- 2012-10-26 WO PCT/US2012/062282 patent/WO2013063510A1/en active Application Filing
- 2012-10-26 CN CN201280065515.9A patent/CN104023748B/zh active Active
- 2012-10-26 CA CA2951856A patent/CA2951856A1/en not_active Abandoned
- 2012-10-26 BR BR112014010186A patent/BR112014010186A2/pt not_active Application Discontinuation
- 2012-10-26 US US13/662,281 patent/US9364542B2/en active Active
- 2012-10-26 CA CA2853823A patent/CA2853823C/en active Active
- 2012-10-26 KR KR1020177019388A patent/KR20170084369A/ko not_active Application Discontinuation
-
2016
- 2016-05-12 US US15/153,680 patent/US20160271253A1/en not_active Abandoned
-
2017
- 2017-08-10 AU AU2017213510A patent/AU2017213510B2/en active Active
-
2018
- 2018-10-29 US US16/174,004 patent/US20190091335A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
KR101759694B1 (ko) | 2017-07-19 |
EP3578203A1 (en) | 2019-12-11 |
BR112014010186A2 (pt) | 2017-05-02 |
CN104023748A (zh) | 2014-09-03 |
AU2012328524B2 (en) | 2017-05-18 |
US20190091335A1 (en) | 2019-03-28 |
KR20170084369A (ko) | 2017-07-19 |
EP2771033A4 (en) | 2016-02-17 |
AU2017213510B2 (en) | 2019-08-01 |
CN104023748B (zh) | 2018-03-02 |
US20160271253A1 (en) | 2016-09-22 |
CA2853823C (en) | 2016-12-20 |
WO2013063510A1 (en) | 2013-05-02 |
CN108771655A (zh) | 2018-11-09 |
KR20140097247A (ko) | 2014-08-06 |
AU2012328524A1 (en) | 2014-05-22 |
US9364542B2 (en) | 2016-06-14 |
CA2951856A1 (en) | 2013-05-02 |
EP2771033A1 (en) | 2014-09-03 |
AU2017213510A1 (en) | 2017-08-31 |
MX2014005106A (es) | 2014-09-22 |
CA2853823A1 (en) | 2013-05-02 |
US20140127227A1 (en) | 2014-05-08 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX352823B (es) | Formulaciones de proteinas que contienen aminoacidos. | |
PH12019500517A1 (en) | Long-acting formulations of insulins | |
AU2013334740A8 (en) | Stable, low viscosity antibody formulation | |
MX2014004725A (es) | Formulaciones de etanercept estabilizadas con aminoacidos. | |
WO2012135805A3 (en) | Delivery and formulation of engineered nucleic acids | |
CL2016001553A1 (es) | Medios para cultivo celular | |
PH12014502778B1 (en) | Antibody formulation | |
WO2014141152A3 (en) | Low concentration antibody formulations | |
MX2014000064A (es) | Composicion detergente liquido. | |
EA033399B1 (ru) | Аналоги глюкагона с повышенной растворимостью и/или стабильностью и их применение | |
WO2011104381A3 (en) | Stable antibody containing compositions | |
AU2012265219A8 (en) | Compounds containing hydrido-tricyano-borate anions | |
NZ717728A (en) | Stable formulations of a hyaluronan-degrading enzyme | |
PH12015500636A1 (en) | Nutritional compositions including a calcium beta-hydroxy-beta-methylbutyrate, protein and low levels of electrolytes | |
BR112016001778A2 (pt) | Célula transgênica de levedura, composição, e, métodos de produção de 3-hp e de produção de ácido acrílico ou um sal do mesmo | |
BR112012021873B8 (pt) | composição de matéria, artigo de manufatura, métodos para preparar uma composição, para aumentar a estabilidade de uma proteína em solução aquosa livre de polissorbato e para prevenir ou reduzir a agregação de uma proteína em solução aquosa livre de polissorbato | |
BR112012032193A2 (pt) | composto, composiçoes e métodos de uso de feniltioacetato | |
EP3878445A3 (en) | Acamprosate formulations, methods of using the same, and combinations comprising the same | |
TR200806298A2 (tr) | Farmasötik formülasyon | |
AR082943A1 (es) | Formula nutricional predigerida | |
BR112016020181A8 (pt) | composições de ácido lipoico éster colina e métodos de uso. | |
BR112014002940A2 (pt) | uso e composição agroquímica de dibutilamidas de ácido carboxílico | |
AR092630A1 (es) | Metodos y composiciones para prevenir la incorporacion erronea de norleucina en proteinas | |
AU2012345659A8 (en) | Acamprosate formulations, methods of using the same, and combinations comprising the same | |
PH12014501307A1 (en) | Liquid activation system |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FG | Grant or registration |